1129P - Pretreatment prognostic factors and early markers for outcome in advanced melanoma treated with nivolumab

Date 09 October 2016
Event ESMO 2016 Congress
Session Poster display
Topics Skin cancers
Presenter Yoshio Nakamura
Citation Annals of Oncology (2016) 27 (6): 379-400. 10.1093/annonc/mdw379
Authors Y. Nakamura1, S. Kitano2, A. Takahashi1, A. Tsutsumida1, K. Namikawa1, I. Muto1, M. Ueno1, Y. Muto1, N. Yamazaki1
  • 1Dermatologic Oncology, National Cancer Center Hospital, 104-0045 - Tokyo/JP
  • 2Experimental Therapeutics, National Cancer Center Hospital, 104-0045 - Tokyo/JP



Anti-programmed cell death protein 1(PD-1) monoclonal antibody, nivolumab, is one of the most effective drugs for advanced melanoma. Serum lactate dehydrogenase (LDH) and cutaneous adverse events have been described as early predictors for outcomes of advanced melanoma treated with nivolumab in some literature. We tried to seek further clinical predictors in daily clinical practice.


We retrospectively analyzed clinical findings of 54 unresectable stage III or IV melanoma patients treated with nivolumab at the National Cancer Center Hospital, Tokyo, Japan, between September 2014 and December 2015. The patients who took steroid orally were excluded from this study. Those patients were administered nivolumab at a dose of 2mg/kg every 3 weeks.


Median overall survival (OS) was 12.7 months. Response rate was 25.9%. Delayed response was shown in only one patient. Patients with baseline ECOG performance status (PS) =0, baseline normal LDH and baseline normal C-related protein (CRP) had significantly longer OS compared with patients with PS ≥ 1 (hazard ratio[HR] 0.25, 95%CI 0.09-0.68, P 


Delayed response may rarely occur in daily clinical practice. ALC ≥ 1000/ml and NLR 

Clinical trial identification

Legal entity responsible for the study

National Cancer Center Hospital


National Cancer Center Hospital


N. Yamazaki: Advisory board role for Chugai Pharma, Bristol-Myers Squibb (BMS) Japan and Ono Pharmaceutical. The institution has received clinical trial support from Chugai, BMS Japan, Ono, GSK, Takeda, AstraZeneca Japan, Boehringer Ingelheim, and Maruho. All other authors have declared no conflicts of interest.